Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM



Fee: There is no fee for this activity

This CME activity is based on the following interactive case study:

Case Study in Refractory Anemia

Ravi Vij,  MD, Washington University in St. Louis School of Medicine

Upon completion of this activity, participants should be able to:

• Understand trilineage response rates among patients with MDS who are treated with azacitidine.
• Evaluate response data from the phase III clinical trial comparing azacitidine to best supportive care in the treatment of MDS.
• Discuss side effects associated with treatment with lenalidomide.
• Understand the role of allogeneic stem cell transplantation among patients with low or intermediate-1 risk MDS.

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters

This activity is supported by an unrestricted educational grant from Pharmion.